Tearsheet

Omada Health (OMDA)


Market Price (5/11/2026): $15.0 | Market Cap: $883.8 Mil
Sector: Health Care | Industry: Health Care Technology

Omada Health (OMDA)


Market Price (5/11/2026): $15.0
Market Cap: $883.8 Mil
Sector: Health Care
Industry: Health Care Technology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24%

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 49%

Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more.

Weak multi-year price returns
2Y Excs Rtn is -80%, 3Y Excs Rtn is -116%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -8.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2.9%

Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 39x

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0%

Key risks
OMDA key risks include [1] a significant revenue concentration with a few key customers and [2] ongoing operating and net losses.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -24%
1 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 49%
2 Megatrend and thematic drivers
Megatrends include Digital Health & Telemedicine, and Aging Population & Chronic Disease. Themes include Telehealth Platforms, Remote Patient Monitoring, Show more.
3 Weak multi-year price returns
2Y Excs Rtn is -80%, 3Y Excs Rtn is -116%
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -8.4 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2.9%
5 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 39x
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.0%
7 Key risks
OMDA key risks include [1] a significant revenue concentration with a few key customers and [2] ongoing operating and net losses.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Omada Health (OMDA) stock has remained largely at the same level since 1/31/2026 because of the following key factors:

1. Consistent Financial Performance and Upgraded Outlook.

Omada Health demonstrated strong financial performance, beating analyst estimates for both the fourth quarter of 2025 and the first quarter of 2026. In Q4 2025, the company reported earnings per share (EPS) of $0.13, surpassing estimates of -$0.05 by $0.18, and revenue of $75.85 million, exceeding estimates by $4.78 million. The company also achieved its first GAAP net income quarter with $5 million in Q4 2025 and positive full-year adjusted EBITDA of $6 million. This positive momentum continued into Q1 2026, with Omada reporting EPS of -$0.05, beating the consensus estimate of -$0.08 by $0.03, and revenue of $78 million, a 42% increase year-over-year. Notably, Q1 2026 marked a positive adjusted EBITDA of $1 million, a $5 million improvement from Q1 2025. Following these results, Omada raised its full-year 2026 revenue guidance to $322 million-$330 million and adjusted EBITDA guidance to $14 million-$20 million. This consistent overperformance and optimistic financial outlook provided a strong underlying support for the stock, preventing significant declines.

2. Strategic Expansion in the GLP-1 Market and PBM Partnerships.

Omada Health significantly expanded its strategic positioning in the rapidly growing GLP-1 medication market during this period. The company announced new partnerships, notably joining Optum Rx's Weight Engage portfolio and Eli Lilly's Employer Connect program in Q1 2026. These collaborations establish relationships with all three leading Pharmacy Benefit Managers (PBMs), which collectively process 80% of prescription claims and serve most commercially insured lives. Through these direct-to-employer and PBM channels, Omada will offer its GLP-1 Care Track, including clinical evaluation, prescribing, and medication management. While these partnerships promise substantial long-term growth and increased market penetration, the material revenue contributions from some of these newer relationships are primarily anticipated in 2027 rather than 2026. This forward-looking revenue realization likely tempered immediate significant upward stock movement, contributing to a stable trading pattern as investors await the full impact of these strategic initiatives.

Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -0.9% change in OMDA stock from 1/31/2026 to 5/10/2026 was primarily driven by a -33.3% change in the company's P/S Multiple.
(LTM values as of)13120265102026Change
Stock Price ($)14.9514.82-0.9%
Change Contribution By: 
Total Revenues ($ Mil)15428383.5%
P/S Multiple4.63.1-33.3%
Shares Outstanding (Mil)4859-19.0%
Cumulative Contribution-0.9%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 5/10/2026
ReturnCorrelation
OMDA-0.9% 
Market (SPY)3.6%35.4%
Sector (XLV)-6.9%21.0%

Fundamental Drivers

The -39.7% change in OMDA stock from 10/31/2025 to 5/10/2026 was primarily driven by a -62.7% change in the company's P/S Multiple.
(LTM values as of)103120255102026Change
Stock Price ($)24.5714.82-39.7%
Change Contribution By: 
Total Revenues ($ Mil)14228399.8%
P/S Multiple8.33.1-62.7%
Shares Outstanding (Mil)4859-19.0%
Cumulative Contribution-39.7%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 5/10/2026
ReturnCorrelation
OMDA-39.7% 
Market (SPY)5.5%29.9%
Sector (XLV)0.3%16.0%

Fundamental Drivers

null
null

Market Drivers

4/30/2025 to 5/10/2026
ReturnCorrelation
OMDA  
Market (SPY)30.4%22.3%
Sector (XLV)4.0%13.4%

Fundamental Drivers

null
null

Market Drivers

4/30/2023 to 5/10/2026
ReturnCorrelation
OMDA  
Market (SPY)78.7%22.3%
Sector (XLV)13.0%13.4%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
OMDA Return-----31%4%-29%
Peers Return-51%-54%7%2%-16%10%-77%
S&P 500 Return27%-19%24%23%16%7%95%

Monthly Win Rates [3]
OMDA Win Rate----29%60% 
Peers Win Rate27%38%50%40%35%55% 
S&P 500 Win Rate75%42%67%75%67%60% 

Max Drawdowns [4]
OMDA Max Drawdown-----37%-31% 
Peers Max Drawdown-56%-68%-29%-49%-30%-34% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-7% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: TDOC, HIMS, GDRX, AMWL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)

How Low Can It Go

OMDA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2025 US Tariff Shock
  % Loss-11.7%-18.8%
  % Gain to Breakeven13.3%23.1%
  Time to Breakeven142 days79 days
2022 Inflation Shock & Fed Tightening
  % Loss-13.8%-24.5%
  % Gain to Breakeven15.9%32.4%
  Time to Breakeven166 days427 days
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-15.0%-19.2%
  % Gain to Breakeven17.6%23.7%
  Time to Breakeven191 days105 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-15.9%-12.2%
  % Gain to Breakeven18.9%13.9%
  Time to Breakeven165 days62 days
2011 US Debt Ceiling Crisis & European Contagion
  % Loss-15.8%-17.9%
  % Gain to Breakeven18.8%21.8%
  Time to Breakeven153 days123 days

Compare to TDOC, HIMS, GDRX, AMWL

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

OMDA has limited trading history. Below is the Health Care sector ETF (XLV) in its place.

EventXLVS&P 500
2020 COVID-19 Crash
  % Loss-27.9%-33.7%
  % Gain to Breakeven38.8%50.9%
  Time to Breakeven77 days140 days
2008-2009 Global Financial Crisis
  % Loss-37.9%-53.4%
  % Gain to Breakeven61.1%114.4%
  Time to Breakeven767 days1085 days

Compare to TDOC, HIMS, GDRX, AMWL

In The Past

State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Omada Health (OMDA)

Omada’s mission is to bend the curve. Our hope is that, one day, tomorrow’s epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada. As part of that mission, we strive to inspire and enable people to make lasting health changes on their own terms. We deliver virtual care between doctor’s visits, providing an engaging, personalized, and integrated experience for our members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers (“PBMs”), and other entities that cover the cost of our programs. As of 2022, more than 156 million Americans suffered from one or more chronic conditions, such as obesity, prediabetes, diabetes, hypertension, and musculoskeletal (“MSK”) conditions, and approximately 40% of U.S. adults suffered from two or more chronic conditions, based on data published in the Annals of Bioethics & Clinical Applications. Managing these conditions—and treating the acute problems they can lead to—creates significant costs for employers, health plans, PBMs, and other entities that pay for the cost of care. According to the American Diabetes Association (the “ADA”)’s report “Economic Costs of Diabetes in the U.S. in 2022,” chronic diseases were the leading driver of U.S. medical spend, with diabetes alone accounting for $1 out of every $7 spent. According to research published in Diabetes Care, in 2022, an employee with type 2 diabetes cost on average an additional $7,000 annually due to increased medical costs, absenteeism, and lost productivity. The direct medical cost of people living with diabetes increased by 35% from 2012 to 2022, despite stable diabetes prevalence. It doesn’t have to be that way. Many chronic conditions can be managed or prevented at a more reasonable cost. One reason these conditions are often not managed efficiently is that the U.S. healthcare system was built mainly on encounter-based reimbursement models that pay for specific services, primarily as issues arise. Between what can be short and infrequent office visits, patients are often left to manage their condition on their own. Many have a hard time sticking to care plans and health goals—losing weight, eating better, exercising more—and have few resources to turn to for ongoing questions, accountability, and support as they work to change their lifestyle. Behavior change is hard. Omada was created to make it easier. Our virtual care programs are rooted in evidence and combine relationship-based, human-led clinical care with purpose-built technology. We call this approach Compassionate Intelligence. We work to develop trust with each member and use technology to help us personalize their experience, enabling us to unlock results at scale. We sell our programs to customers that cover the cost for covered individuals. Our customers include employers that cover our programs for their employees and their dependents, health systems that cover our programs for patients, and any other entity that is financially responsible for costs of our programs for a population of covered lives. We also work closely with health plans and PBMs that either cover our programs for a portion of their members as our customers or act as channel partners reselling our programs to their own end customers. Our channel partners’ end customers typically consist of employers that cover our programs for their employees and their dependents. In general, our customers cover the cost of our programs for our members, except that members in our physical therapy program may incur copays, coinsurance, or deductibles, depending on plan design, much like in-person physical therapy. We launched our initial program in diabetes prevention and weight health in 2012, with the goal of showing that a virtual program could achieve the same clinical results as its in-person archetype. Through feedback from our customers, channel partners, members, and the market at large, we then recognized the need to create an integrated, multi-condition care platform to address multiple, commonly comorbid, chronic conditions. Today, we offer cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address MSK conditions; additional support for members taking glucagon-like peptide-1 agonists (“GLP-1”) in our cardiometabolic programs (“GLP-1 Care Tracks”); and behavioral health support across all programs. Since our founding, our programs have had a meaningful, positive impact. As of March 31, 2025, we had more than 2,000 customers and over 679,000 total members enrolled in one or more programs, and we had supported over one million members since launch. We count a member as enrolled in a program to the extent their participation was billed at least once in the preceding 12 months. We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates. In 2024, our average customer satisfaction rate for the year was over 90% for each of program implementation and customer success. Our customer satisfaction rate is based on survey results from customers that launched a new program during the measured period, and we consider a customer to be satisfied if they rated our program implementation and ongoing customer success, as applicable, at a 5 or higher on a 7-point scale. We believe that our customer satisfaction rates are strong and reflect the value of our services to customers. In 2024, more than 55% of members still engaged with our cardiometabolic programs at least once per month after a year in the program, and over 50% still engaged monthly after two years. We consider members to be still engaged after one year or two years in the program if, during their twelfth or twenty-fourth month of program participation in a cardiometabolic program, they complete at least one interaction with us, such as logging in or interacting with the Omada mobile app, sending messages to Omada Care Team members, or recording metrics such as weight, blood pressure, or blood glucose values. On average, in 2024, members in a cardiometabolic program engaged more than 30 times per month throughout their first year. Based on our experience and feedback from customers, we believe these engagement rates to be positive and to demonstrate the attractiveness of our program to members. We are proud of our progress, and we are just getting started. We have experienced strong growth since our inception. Revenue increased by 38% from $122.8 million to $169.8 million for the years ended December 31, 2023 and 2024, respectively, and by 57% from $35.1 million to $55.0 million for the three months ended March 31, 2024 and 2025, respectively. We continue to generate revenue from recurring customers, as evidenced by our net dollar retention rate, which for customers who were contracted as of the beginning of the prior period, is calculated as total billings generated in a particular period divided by total billings generated in the prior period and was 110% and 128% for the years ended December 31, 2023 and 2024, respectively. We have a history of net losses, due in part to the significant investments we have made in the design and development of our programs and platform enhancements, and have not yet achieved profitability on an annual basis. Our principal executive offices are located San Francisco, California.

AI Analysis | Feedback

Noom for chronic diseases.

A virtual Weight Watchers for managing chronic conditions like diabetes and hypertension.

AI Analysis | Feedback

```html
  • Cardiometabolic Programs: Virtual care programs designed to manage and prevent prediabetes, diabetes, and hypertension.
  • Physical Therapy Program: A virtual program addressing musculoskeletal (MSK) conditions.
  • GLP-1 Care Tracks: Specialized support integrated into cardiometabolic programs for members using glucagon-like peptide-1 agonists.
  • Behavioral Health Support: Integrated behavioral health services offered across all Omada programs to enhance overall well-being.
```

AI Analysis | Feedback

Omada Health (OMDA) sells its programs primarily to other companies and entities that cover the cost for individuals. Based on the provided description, the company does not name specific customer companies. Instead, it identifies the following categories of organizations as its major customers and channel partners:

  • Employers: These entities cover Omada's programs for their employees and their dependents.
  • Health Systems: These entities cover Omada's programs for their patients.
  • Health Plans: These entities either cover Omada's programs for a portion of their members as direct customers or act as channel partners reselling the programs.
  • Pharmacy Benefit Managers ("PBMs"): These entities act as channel partners, reselling Omada's programs to their own end customers, which are typically employers.

AI Analysis | Feedback

null

AI Analysis | Feedback

Sean Duffy, Co-Founder & Chief Executive Officer

Sean Duffy co-founded Omada Health in 2011 with the goal of revolutionizing healthcare for chronic diseases by merging medical trends and technology. Before Omada Health, he created Excel Everest, an interactive Microsoft Excel training tool, and worked as an editor for Medgadget, a medical technology blog. He also held roles at Google and IDEO. Duffy began his journey with a background in medicine and technology, having pursued dual MD/MBA degrees at Harvard.

Steve Cook, Chief Financial Officer

Steve Cook joined Omada Health as Chief Financial Officer in 2021. He brings over a decade of experience in financial strategy, having previously served as Vice President and Head of Strategic Finance at One Medical, where he guided their strategic finance efforts through its 2020 IPO. Prior to that, Cook spent six years in finance and strategy at Salesforce.

Wei-Li Shao, President

Wei-Li Shao joined Omada Health in 2019 and serves as its President. He has over 20 years of global healthcare experience, including executive roles at Eli Lilly and Company, where he built and led biopharmaceutical and diagnostic imaging businesses in various countries, including the United States, China, and New Zealand.

Carolyn Jasik, Chief Medical Officer

Carolyn Jasik serves as the Chief Medical Officer of Omada Health. She brings expertise in clinical care and is instrumental in integrating medical best practices within Omada's virtual care programs.

Sunil Kayiti, Chief Technology Officer

Sunil Kayiti is the Chief Technology Officer at Omada Health. He is responsible for the technology and platform enhancements that support Omada's virtual care programs.

AI Analysis | Feedback

The key risks to Omada Health's business include:

  1. History of Net Losses and Path to Profitability: Omada Health has a history of net losses and has not yet achieved profitability on an annual basis, which is attributed to significant investments in program and platform enhancements.

  2. Reliance on Customers, Channel Partners, and Evolving Reimbursement Models: Omada Health's revenue is dependent on securing and retaining contracts with employers, health plans, health systems, pharmacy benefit managers ("PBMs"), and other entities that cover the cost of their programs for covered individuals. Changes in the willingness of these customers and channel partners to cover or resell Omada's programs, or shifts in the broader healthcare reimbursement landscape, could significantly impact the company's financial performance.

AI Analysis | Feedback

null

AI Analysis | Feedback

Null

AI Analysis | Feedback

Expected Drivers of Future Revenue Growth for Omada Health (OMDA) over the Next 2-3 Years:

  1. Expansion and Adoption of GLP-1 Related Programs: Omada Health anticipates significant revenue growth from its GLP-1 Care Track, driven by employer demand to maximize the value of their GLP-1 investments. The company has launched new offerings, including GLP-1 prescribing and GLP-1 Flex Care, which provides employers with a structured way to connect eligible employees with clinical evaluation, prescribing, and ongoing medical oversight for GLP-1s alongside Omada's lifestyle and behavioral support. This initiative is expected to cater to the growing market for anti-obesity medications and associated care.
  2. Growth of the Multi-Condition Care Platform and New Condition Launches: Omada continues to expand the reach and depth of its integrated multi-condition care platform, which already addresses cardiometabolic conditions (prediabetes, diabetes, hypertension), musculoskeletal (MSK) conditions, and behavioral health. The launch of "Omada for Cholesterol" in February 2026 further strengthens its cardiometabolic offerings and expands the scope of its platform, allowing the company to address more prevalent and often comorbid chronic conditions.
  3. Customer Acquisition and Deeper Penetration within Existing Customer Accounts: Omada Health's revenue growth is also expected from acquiring new customers, which include employers, health plans, health systems, and pharmacy benefit managers (PBMs). Furthermore, the company aims for deeper penetration within its existing customer base, expanding the number of programs and members covered per account. Omada's strong customer satisfaction and high net dollar retention rates (128% in 2024) indicate successful existing relationships that can drive further expansion.
  4. Leveraging Artificial Intelligence (AI) for Enhanced Engagement and Program Efficacy: Omada is strategically investing in and deploying AI-powered tools, such as OmadaSpark and Meal Map, launched in 2025, to enhance member engagement and optimize care delivery. These AI-supported tools are designed to provide personalized healthcare experiences, offer 24/7 access to resources, and assist human-led care teams, ultimately contributing to better health outcomes and increased member retention, which indirectly supports revenue growth.

AI Analysis | Feedback

Share Issuance

  • Omada Health completed its Initial Public Offering (IPO) in June 2025, offering 7.9 million shares at $19.00 per share.
  • The IPO successfully raised $150 million for the company.
  • The offering included a 30-day option for underwriters to purchase up to an additional 1.185 million shares.

Inbound Investments

  • Prior to its IPO, Omada Health had raised over $500 million in total funding.
  • In February 2022, the company secured $192 million through a Series E funding round, which led to its valuation as a unicorn.

Better Bets vs. Omada Health (OMDA)

Trade Ideas

Select ideas related to OMDA.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
GEHC_4302026_Dip_Buyer_FCFYield04302026GEHCGE HealthCare TechnologiesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
IQV_4302026_Dip_Buyer_FCFYield04302026IQVIQVIADip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
UHS_4302026_Dip_Buyer_FCFYield04302026UHSUniversal Health ServicesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
ABT_4302026_Dip_Buyer_ValueBuy04302026ABTAbbott LaboratoriesDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
0.0%0.0%0.0%
ZBIO_4302026_Insider_Buying_45D_2Buy_200K04302026ZBIOZenas BioPharmaInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days
0.0%0.0%0.0%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

OMDATDOCHIMSGDRXAMWLMedian
NameOmada He.Teladoc .Hims & H.GoodRx American. 
Mkt Price14.827.2528.272.927.977.97
Mkt Cap0.90.06.41.00.10.9
Rev LTM2832,5142,348788237788
Op Inc LTM-8-15710678-92-8
FCF LTM161275797-4557
FCF 3Y Avg-16910187-11394
CFO LTM23288300170-42170
CFO 3Y Avg-311208157-104182

Growth & Margins

OMDATDOCHIMSGDRXAMWLMedian
NameOmada He.Teladoc .Hims & H.GoodRx American. 
Rev Chg LTM49.4%-1.5%59.0%-1.2%-9.3%-1.2%
Rev Chg 3Y Avg43.8%0.7%64.6%1.8%-4.9%1.8%
Rev Chg Q42.0%-2.5%28.4%-4.4%-17.9%-2.5%
QoQ Delta Rev Chg LTM8.9%-0.6%6.2%-1.1%-4.8%-0.6%
Op Inc Chg LTM75.5%15.8%70.6%-4.6%46.6%46.6%
Op Inc Chg 3Y Avg45.2%11.0%146.0%-0.1%28.1%28.1%
Op Mgn LTM-2.9%-6.3%4.5%9.9%-38.9%-2.9%
Op Mgn 3Y Avg-23.2%-7.4%1.8%5.4%-69.5%-7.4%
QoQ Delta Op Mgn LTM1.7%0.2%-0.7%-1.1%3.3%0.2%
CFO/Rev LTM8.0%11.5%12.8%21.6%-17.6%11.5%
CFO/Rev 3Y Avg-12.1%12.7%20.0%-41.1%12.4%
FCF/Rev LTM5.8%5.0%2.4%12.3%-18.8%5.0%
FCF/Rev 3Y Avg-6.6%7.1%11.2%-44.6%6.8%

Valuation

OMDATDOCHIMSGDRXAMWLMedian
NameOmada He.Teladoc .Hims & H.GoodRx American. 
Mkt Cap0.90.06.41.00.10.9
P/S3.10.02.71.30.61.3
P/Op Inc-104.5-0.360.812.7-1.4-0.3
P/EBIT-181.1-0.360.811.4-1.4-0.3
P/E-138.6-0.350.048.4-1.5-0.3
P/CFO38.70.221.45.8-3.25.8
Total Yield-0.7%-395.4%2.0%2.1%-66.5%-0.7%
Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%
FCF Yield 3Y Avg-338.8%2.3%7.4%-72.2%4.9%
D/E0.024.00.20.50.00.2
Net D/E-0.26.60.10.3-1.30.1

Returns

OMDATDOCHIMSGDRXAMWLMedian
NameOmada He.Teladoc .Hims & H.GoodRx American. 
1M Rtn29.9%42.2%45.5%33.3%53.6%42.2%
3M Rtn27.2%44.7%22.8%19.7%79.5%27.2%
6M Rtn-27.0%-3.7%-31.1%-6.1%89.3%-6.1%
12M Rtn-35.6%2.0%-45.6%-32.4%16.5%-32.4%
3Y Rtn-35.6%-70.8%167.5%-41.8%-81.6%-41.8%
1M Excs Rtn15.3%29.7%34.7%26.8%38.6%29.7%
3M Excs Rtn20.5%38.0%16.1%12.9%72.8%20.5%
6M Excs Rtn-45.3%-18.9%-44.2%-21.2%65.5%-21.2%
12M Excs Rtn-67.0%-25.7%-77.4%-54.3%-13.8%-54.3%
3Y Excs Rtn-116.4%-152.7%57.5%-113.9%-162.1%-116.4%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil202520242023
Virtual care program product offering17012389
Total17012389


Net Income by Segment
$ Mil202520242023
Virtual care program product offering-47-68 
Total-47-68 


Price Behavior

Price Behavior
Market Price$14.82 
Market Cap ($ Bil)0.9 
First Trading Date06/06/2025 
Distance from 52W High-44.7% 
   50 Days200 Days
DMA Price$18.91$18.91
DMA Trenddownup
Distance from DMA-21.6%-21.6%
 3M1YR
Volatility56.3%65.4%
Downside Capture0.601.24
Upside Capture205.99120.85
Correlation (SPY)28.6% 
OMDA Betas & Captures as of 4/30/2026

 1M2M3M6M1Y3Y
Beta1.661.381.431.41-0.040.08
Up Beta1.271.180.800.730.33-0.66
Down Beta-8.980.090.670.780.20-0.69
Up Capture208%231%186%111%97%9%
Bmk +ve Days15223166141428
Stock +ve Days13253462113113
Down Capture485%140%193%202%161%82%
Bmk -ve Days4183056108321
Stock -ve Days8172960108108

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with OMDA
OMDA-37.6%65.5%-0.52-
Sector ETF (XLV)7.9%15.4%0.3013.8%
Equity (SPY)29.0%12.5%1.8322.8%
Gold (GLD)39.8%27.0%1.22-2.0%
Commodities (DBC)50.6%18.0%2.21-7.8%
Real Estate (VNQ)13.0%13.5%0.668.9%
Bitcoin (BTCUSD)-17.4%42.1%-0.3415.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with OMDA
OMDA-9.0%65.5%-0.52-
Sector ETF (XLV)4.9%14.6%0.1613.8%
Equity (SPY)12.8%17.1%0.5922.8%
Gold (GLD)20.9%17.9%0.95-2.0%
Commodities (DBC)13.8%19.1%0.59-7.8%
Real Estate (VNQ)3.4%18.8%0.088.9%
Bitcoin (BTCUSD)7.0%56.0%0.3415.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with OMDA
OMDA-4.6%65.5%-0.52-
Sector ETF (XLV)9.3%16.5%0.4613.8%
Equity (SPY)15.1%17.9%0.7222.8%
Gold (GLD)13.4%15.9%0.69-2.0%
Commodities (DBC)9.3%17.8%0.44-7.8%
Real Estate (VNQ)5.8%20.7%0.248.9%
Bitcoin (BTCUSD)67.8%66.9%1.0715.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date4152026
Short Interest: Shares Quantity3.7 Mil
Short Interest: % Change Since 33120263.3%
Average Daily Volume0.7 Mil
Days-to-Cover Short Interest5.5 days
Basic Shares Quantity58.9 Mil
Short % of Basic Shares6.2%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
3/5/20263.3%3.1%-7.5%
11/6/2025-7.1%-5.0%-28.4%
8/7/2025-2.3%4.9%23.5%
SUMMARY STATS   
# Positive121
# Negative212
Median Positive3.3%4.0%23.5%
Median Negative-4.7%-5.0%-18.0%
Max Positive3.3%4.9%23.5%
Max Negative-7.1%-5.0%-28.4%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/08/202610-Q
12/31/202503/06/202610-K
09/30/202511/07/202510-Q
06/30/202508/08/202510-Q
03/31/202506/09/2025424B4
12/31/202302/14/2025DRS/A

Recent Forward Guidance [BETA]

Latest: Q1 2026 Earnings Reported 5/7/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue322.00 Mil326.00 Mil330.00 Mil2.8% RaisedGuidance: 317.00 Mil for 2026
2026 Adjusted EBITDA14.00 Mil17.00 Mil20.00 Mil54.5% RaisedGuidance: 11.00 Mil for 2026

Prior: Q4 2025 Earnings Reported 3/5/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Revenue312.00 Mil317.00 Mil322.00 Mil23.4% Higher NewActual: 257.00 Mil for 2025
2026 Adjusted EBITDA7.00 Mil11.00 Mil15.00 Mil   

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Shao, Wei-LiPresidentDirectSell410202612.712,82935,9464,178,434Form
2Cook, Steven LChief Financial OfficerDirectSell317202613.941,88426,2632,795,137Form
3Duffy, Sean PChief Executive OfficerDirectSell311202614.344,06358,2761,686,726Form
4Duffy, Sean PChief Executive OfficerDirectSell114202615.9540,796650,7742,020,212Form
5Duffy, Sean PChief Executive OfficerDirectSell114202615.60230,4793,595,1521,975,470Form